|
Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs. |
| |
|
Employment - Novartis (I) |
Stock and Other Ownership Interests - Veris Health |
Consulting or Advisory Role - AstraZeneca; AstraZeneca/Daiichi Sankyo; bioTheranostics; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Seagen; Stemline Therapeutics |
Speakers' Bureau - AstraZeneca; Lilly |
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celcuity; Daiichi Sankyo; EMD Serono; Genentech/Roche; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Myriad Genetics; Natera; Puma Biotechnology; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Consulting or Advisory Role - G1 therapeutics; Janssen |
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst) |
Patents, Royalties, Other Intellectual Property - Pat pending |
| |
|
Employment - West Cancer Center and Research Institute |
Speakers' Bureau - Bristol Myers Squibb Foundation |
Travel, Accommodations, Expenses - West Cancer Center and Research Institute |
| |
|
Consulting or Advisory Role - Gilead Sciences; Macrogenics; Novartis |
Research Funding - Novartis; Pfizer; Sanofi; Seagen |
| |
|
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Genentech/Roche; Janssen Oncology; Lilly; Merck; merus; Novartis; Pfizer; Takeda; Turning Point Therapeutics; Veracyte |
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst) |
| |
|
Employment - UAB Hospital |
| |
|
Honoraria - Genentech/Roche; Regenxbio |
Consulting or Advisory Role - Novartis |
Research Funding - EyeBio (Inst); EyePoint Pharmaceuticals (Inst); Genentech (Inst); Kodiak Sciences (Inst); Novartis (Inst); Ocular Therapeutix (Inst); Regenxbio (Inst) |
Travel, Accommodations, Expenses - Genentech; Regenxbio |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Company (Inst); Cantargia AB (Inst); Caris Life Sciences (Inst); DynamiCure Biotechnology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Henlius (Inst); Henlius (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Lilly (Inst); Loxo/Lilly (Inst); Lucence (Inst); Merck (Inst); National Cancer Institute (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); Numab (Inst); Orum Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst); Xencor (Inst); Xencor (Inst) |
| |
|
Consulting or Advisory Role - Merck; Novartis; Regeneron |
|
Research Funding - Exelixis |
| |
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb USA; EMD Serono; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; Regeneron |
Consulting or Advisory Role - Mirati Therapeutics |
Speakers' Bureau - BMS; EMD Serono; G1 Therapeutics; Jazz Pharmaceuticals; Mirati Therapeutics; Regeneron |
Research Funding - BMS; Genentech; Mirati Therapeutics |
Travel, Accommodations, Expenses - BMS; Regeneron |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
| |
|
Employment - Genentech/Roche; Loyal (Biotech) (I) |
Stock and Other Ownership Interests - Genentech/Roche |
Honoraria - Massachusetts General Hospital Cancer Center |
| |
|
Employment - Genentech/Roche; Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
| |
|
Consulting or Advisory Role - Genentech/Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
| |
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |